These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 28629392

  • 1. Do investors value the FDA orphan drug designation?
    Miller KL.
    Orphanet J Rare Dis; 2017 Jun 19; 12(1):114. PubMed ID: 28629392
    [Abstract] [Full Text] [Related]

  • 2. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 3. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E.
    Orphanet J Rare Dis; 2017 Jan 05; 12(1):1. PubMed ID: 28057032
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT.
    Adv Exp Med Biol; 2017 Jan 05; 1031():183-196. PubMed ID: 29214572
    [Abstract] [Full Text] [Related]

  • 7. Adoption agents.
    Wapner J.
    Sci Am; 2010 Jun 05; 302(6):19-20. PubMed ID: 20521471
    [No Abstract] [Full Text] [Related]

  • 8. The Orphan Drug Act Revisited.
    Thomas S, Caplan A.
    JAMA; 2019 Mar 05; 321(9):833-834. PubMed ID: 30768155
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C, Rusch LM.
    J Clin Pharmacol; 2016 Mar 05; 56(3):257-9. PubMed ID: 26211513
    [No Abstract] [Full Text] [Related]

  • 14. The Orphan Drug Act. The first 7 years.
    Asbury CH.
    JAMA; 1991 Feb 20; 265(7):893-7. PubMed ID: 1992188
    [Abstract] [Full Text] [Related]

  • 15. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG, Pawlik TM, Fader AN, Esnaola NF, Makary MA.
    Am J Clin Oncol; 2016 Apr 20; 39(2):210-3. PubMed ID: 26580246
    [Abstract] [Full Text] [Related]

  • 16. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G.
    Wall St J (East Ed); 2005 Nov 15; ():A1, A18. PubMed ID: 16502531
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E.
    Nat Rev Drug Discov; 2010 Dec 15; 9(12):921-9. PubMed ID: 21060315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.